Enhancing immunotherapy treatment response with a novel molecular glue degrader of the corest complex in triple-negative breast cancer

Active Project Grant Awarded Last action

Award ID
HT9425261E464
Recipient
Awarding agency
Obligated
$1,499,999

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 0% complete
Place of performance
Gainesville, FL 32611, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Defense Health Agency awarded the University of Florida Division of Sponsored Research $1.499 million on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to enhance immunotherapy treatment response in triple-negative breast cancer through development of a novel molecular glue degrader of the COREST complex. Work is performed in Gainesville, Florida, with a period of performance extending through October 31, 2029.

Quick answers

Who received award HT9425261E464?

HT9425261E464 was awarded to University Of Florida by Defense Health Agency (Department of Defense) on November 1, 2026.

How much is award HT9425261E464 worth?

$1,499,999 has been obligated on HT9425261E464.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login